Every Form 4 that Becton, Dickinson and Co. (BDX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BDX filings page.
Becton, Dickinson and Company executive Pavan Mocherla, EVP & President, Greater Asia, reported equity awards in company stock. On 11/26/2025, he acquired 2,208 shares of common stock, described as restricted stock units granted under the company’s 2004 Employee and Director Equity-Based Compensation Plan, at a reporting price of $0 per share. After this grant, he beneficially owned 5,055 shares directly.
On the same date, he also acquired 708 shares of common stock at a reporting price of $0 per share, identified as shares received upon vesting of performance-based equity awards, bringing his directly owned total to 5,763 shares. The filing is made on Form 4, which discloses changes in the insider’s beneficial ownership of Becton Dickinson & Co (BDX) common stock.
Becton, Dickinson and Company executive David Shan reported equity transactions in BDX stock. On 11/26/2025, he received 3,504 restricted stock units under the company’s 2004 Employee and Director Equity-Based Compensation Plan and 1,025 shares from vesting of performance-based equity awards, both at a stated price of $0 per share as these are compensation-related grants.
On the same date, 134 shares of common stock were withheld to cover taxes related to these vestings. After these transactions, Shan directly beneficially owned 8,970 shares of Becton Dickinson common stock. He is listed as an Executive Vice President and Chief ISC Officer, and the filing is made for one reporting person.
Becton, Dickinson and Company executive equity activity: Executive Vice President and Chief People Officer Shana Carol Neal reported equity transactions in Becton Dickinson & Co common stock. On 11/26/2025, she acquired 6,727 shares of common stock as restricted stock units granted under the company’s 2004 Employee and Director Equity-Based Compensation Plan, and 3,525 shares received upon vesting of performance-based equity awards, both at a stated price of $0 per share. The filing also reports 2,454 shares withheld to cover taxes related to the vesting of these performance units and previously reported restricted stock units. After these transactions, she directly beneficially owned 21,326 shares of Becton Dickinson common stock.
Becton, Dickinson and Company executive Roland Goette, EVP and President, EMEA, reported routine equity compensation activity. On 11/26/2025, he acquired 1,906 shares of common stock from restricted stock units granted under the company’s 2004 equity-based compensation plan and 1,237 shares received upon vesting of performance-based equity awards, both at a price of $0 as these are compensation grants.
On the same date, 138 shares were disposed of at a stated price of $0 to cover withholding taxes related to the vesting events. After these transactions, Goette directly owned 17,222 shares of common stock and indirectly held 1,559 shares through the Global Share Investment Program as of November 24, 2025.
Becton, Dickinson and Company executive equity transaction: On 11/26/2025, EVP & President, Medical Essential & BioPharm, Michael David Garrison reported multiple equity-related transactions in Becton Dickinson & Co common stock.
He acquired 7,568 shares as restricted stock units awarded under the company’s 2004 Employee and Director Equity-Based Compensation Plan and 3,048 shares received upon vesting of performance-based equity awards, both at a price of $0 per share. In connection with these vestings, 1,769 shares were withheld to cover withholding taxes.
Following these transactions, he beneficially owned 13,734 shares of Becton Dickinson & Co common stock in direct ownership.
Becton Dickinson & Co executive reports equity award activity. Michael Feld, EVP, CRO & President, Life Sciences, reported transactions in Becton Dickinson & Co common stock on 11/26/2025. He acquired 8,829 shares at a price of $0, reflecting the vesting of restricted stock units granted under the company’s 2004 Employee and Director Equity-Based Compensation Plan.
On the same date, 419 shares were disposed of at $0 to cover withholding taxes related to the vesting of previously reported restricted stock units. After these transactions, Feld directly beneficially owned 16,655 shares of Becton Dickinson & Co common stock.
Becton Dickinson & Co. executive vice president and chief financial officer Christopher DelOrefice reported routine equity award activity. On 11/26/2025, he acquired 6,006 shares of common stock at $0 per share, representing shares received upon vesting of performance-based equity awards. On the same date, 4,245 shares were disposed of at $0 per share, reflecting shares withheld to cover tax obligations tied to this vesting and previously granted restricted stock units. After these transactions, DelOrefice directly beneficially owned 22,982 shares of Becton Dickinson common stock.
Becton, Dickinson and Company executive equity transactions
Richard Byrd, EVP & President Interventional of Becton, Dickinson and Company, reported equity transactions dated 11/26/2025. He acquired 6,447 shares of common stock as restricted stock units granted under the company’s 2004 Employee and Director Equity-Based Compensation Plan, and 2,385 shares received upon vesting of performance-based equity awards, both at a stated price of $0 per share, reflecting stock-based compensation rather than open‑market purchases.
To cover withholding taxes related to the vesting of these performance units and previously reported restricted stock units, 1,719 shares were withheld and reported as disposed of at a price of $0 per share. Following these transactions, Byrd directly beneficially owned 13,849 shares of Becton Dickinson common stock.
Becton, Dickinson and Company executive receives stock-based compensation grant
Becton, Dickinson and Company reported that an officer, serving as EVP & President Connected Care, acquired 9,530 shares of common stock on 11/26/2025. The shares are in the form of restricted stock units granted at a price of $0 under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. Following this grant, the reporting person beneficially owns 21,751 shares of Becton Dickinson common stock in direct ownership.
Becton Dickinson & Co. reported equity award activity for its Chairman, CEO and President. On 11/26/2025, the executive acquired 22,521 shares of common stock at $0, representing shares received upon vesting of performance-based equity awards. On the same date, 17,421 shares of common stock were disposed at $0, representing shares withheld to cover taxes related to these performance units and previously reported restricted stock units.
The executive’s directly owned common stock after these transactions totaled 105,471 shares. In addition, the executive was granted stock appreciation rights covering 165,581 shares of common stock with a conversion or exercise price of $193.9 per share. These stock appreciation rights become exercisable in four annual installments beginning on 11/26/2026 and expire on 11/26/2035, and are held directly.
Becton, Dickinson and Company (BDX) reported an insider transaction on Form 4. Director Bertram L. Scott sold 217 shares of common stock at $176.58 on 11/07/2025. Following the sale, he beneficially owns 35,816 shares held directly. The filing was submitted by one reporting person.
Becton, Dickinson and Company (BDX) director Carrie L. Byington reported an acquisition of derivative securities. On 11/04/2025, she acquired 34 rights to common stock under the BD Deferred Compensation Plan at a price of $178.71 per derivative security.
Following the transaction, she beneficially owns 1,675 derivative securities, held directly. Each right converts into one share of common stock. According to the plan terms, the securities are distributed after the director’s service ends or on dates the director specifies.
Becton, Dickinson and Company (BDX) reported a Form 4 for director Christopher Jones. On 11/04/2025, he acquired 168 derivative securities described as rights to common stock under the BD Deferred Compensation Plan, coded “A.” The filing lists a price of $178.71 for the derivative security.
Following this transaction, Jones beneficially owns 11,316 derivative securities on a direct basis. The securities convert to common stock on a one-for-one basis and are distributed following the end of his service as a director or on the date(s) he specifies. The filing notes that totals include rights acquired through dividend investment since the last report.
Becton Dickinson (BDX) reported an insider transaction by its EVP & President, Life Sciences. On 10/27/2025, the officer sold 57 shares of common stock at $186.01 per share. Following the sale, the officer beneficially owns 8,245 shares, held directly.
The filing notes the trade was made pursuant to a Rule 10b5-1 plan adopted on February 7, 2025, indicating a pre-set trading arrangement.
Michael Feld, EVP & President, Life Sciences at Becton Dickinson & Co (BDX), reported a sale of 58 shares of common stock at $181.03 per share on 09/26/2025, leaving him with 8,302 shares beneficially owned. The filing notes the sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 2, 2024.